New Pill-Infusion combo takes on Hard-to-Treat cancers
NCT ID NCT06220318
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the combination can shrink tumors or slow cancer growth. It is an early-stage study, so the main goals are to understand side effects and get a first look at effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C019199 (oral tablet) combined with sintilimab (intravenous infusion)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with only 155 participants, so results may not apply to everyone. The combination may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China